AB SCIEX Announces Company’s First In Vitro Diagnostic Device
FRAMINGHAM, Mass.--(BUSINESS WIRE)--Feb 12, 2013--AB SCIEX, a global leader in analytical technologies, today introduced the AB SCIEX API 3200MD™ and 3200MD QTRAP®LC/MS/MS systems*, two devices that can be used to analyze trace levels of multiple compounds in human samples for diagnostic purposes.
Mass spectrometry is an analytical technology that has the potential to improve the quality of results for use in clinical diagnostics, while reducing costs compared to other technologies.
“Clinical diagnostics is the new frontier for mass spectrometry,” said Rainer Blair, President of AB SCIEX. “The introduction of the 3200MD series is a major milestone for AB SCIEX itself in response to the demand in clinical settings for mass spectrometers as medical devices that meet regulatory requirements.” The 3200MD series is the first of a family of in vitro diagnostic devices that AB SCIEX plans to roll out around the world in the future. The intended use of these devices is to identify inorganic or organic compounds in human specimens for clinical use.
The introduction of this new family of in vitro diagnostic devices follows up AB SCIEX’s announcement in 2012 of obtaining ISO 13485:2003 certification. ISO 13485:2003 is an ISO standard that represents the requirements for a comprehensive quality management system for the design and manufacture of medical devices.
AB SCIEX is a global company with more than 25 years of innovation and market leadership in mass spectrometry. Its instrumentation is used in biomedical research, drug discovery and development, food safety testing, clinical research and forensic toxicology.
* Not available in every country. Contact a local AB SCIEX representative for more information.
About AB SCIEX
AB SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to push the limits in their field and address the complex analytical challenges they face. The company’s global leadership and world-class service and support in the mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research. With over 25 years of proven innovation, AB SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. For more information about the company, go to www.absciex.com. Follow AB SCIEX on Twitter @ABSCIEX, Facebook and LinkedIn.